Scientific Contributions

We are pleased to have contributed multiple articles to the Italian special edition of ACS Medicinal Chemistry Letters, highlighting the world-class drug discovery research taking place at IRBM. One of our studies featured in this publication, deals with an exploratory program…

Earlier this year, we published a paper in Molecular Pharmaceutics that highlights our work with the CHDI Foundation to develop therapeutics that substantially improve the lives of those affected by Huntington’s disease. It is essential to understand the physiochemical properties…

At IRBM, we are aware that a screening campaign’s success is critically dependent on the quality and reproducibility of the assays used. Together with the NIH, academic institutions and pharmaceutical companies, we are participating in an EATRIS consortium initiative to…

In a recent publication for The Journal of Clinical Investigation, IRBM and our international collaborators report exciting findings regarding a potential treatment for Huntington’s disease. We found elevated levels of the active proteinase ADAM10 in the presence of the polyglutamine-expanded…

The American Chemical Society recently dedicated an issue of its ACS Medicinal Chemistry Letters journal to medicinal chemistry in Italy.  As the editor’s introduction to this issue outlines, Italy has a strong track record in this field. This includes the…

We are delighted that positive outcomes of our contribution to the “Magic Bullet” project developed under the Marie Skłodowska-Curie Actions research fellowship program are being recognized. One important example is this recently published paper in Pharmaceutics that we co-authored. The…

Our recent study published in the Journal of Pharmaceutical and Biomedical Analysis details a novel protocol using NMR for plasma protein binding (PPB) assessment in drug discovery research. PPB is the degree to which therapeutics attach to proteins in the…